Metformin with Standard Therapy for Advanced Soft Tissue Sarcoma
This study is looking at how adding Metformin Hydrochloride to your regular (standard of care) treatment might help people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread (metastatic). We want to see if this combination improves how long people live. You might be able to join if you are 18 or older, have advanced soft tissue sarcoma, and are about to start your first systemic treatment for this advanced disease. The study aims to enroll 50 participants and will measure how many participants are still alive at 12 months after starting Metformin.
- Study design
- This is a single-arm study, meaning everyone receives the same treatment. It is open-label, so you and your doctor will know you are receiving Metformin. The study plans to include 50 participants.
- What's involved
- You will take Metformin Hydrochloride by mouth daily for up to 5 years or until your treatment is stopped early. You will also have an office visit around 15 days after starting Metformin to check how you are tolerating the dose.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track how long participants survive for at least 12 months from the start of Metformin.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Megan Jagosky, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants surviving at 12 monthsFrom date of metformin start to date of death, or censored at 12 months, whichever occurred first.
12-month overall survival (OS) will be determined for each participant as a binary variable indicating whether the participant was surviving at 12 months after study enrollment. Failure occurs if the participant dies from any cause within 12 months of study enrollment (initiation of metformin).